Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imaging

Study Type – Diagnostic (exploratory cohort) 
Level of Evidence 2b

[1]  Katarzyna J Macura,et al.  Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. , 2009, Radiology.

[2]  G. Haas,et al.  Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer , 2009, BJU international.

[3]  Tristan Barrett,et al.  Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. , 2007, AJR. American journal of roentgenology.

[4]  L. Turnbull,et al.  Description of magnetic resonance imaging‐derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions , 2009, BJU international.

[5]  [Quantitative dynamic MRI and localisation of non-palpable prostate cancer]. , 2009, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[6]  A. Evans,et al.  Prostate cancer detection with multi‐parametric MRI: Logistic regression analysis of quantitative T2, diffusion‐weighted imaging, and dynamic contrast‐enhanced MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[7]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[8]  Deanna L Langer,et al.  Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. , 2008, Radiology.

[9]  L. Chauveinc,et al.  IRM dynamique quantitative et localisation du cancer de prostate non palpable , 2009 .

[10]  Fernando J. Kim,et al.  Combined T 2-weighted and diffusion-weighted MRI for localization of prostate cancer , 2007 .

[11]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[12]  A. Villers,et al.  Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. , 2006, The Journal of urology.

[13]  Xavier Leroy,et al.  Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. , 2009, Urology.

[14]  Evis Sala,et al.  Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. , 2006, Radiology.

[15]  J H Ellis,et al.  MR imaging and sonography of early prostatic cancer: pathologic and imaging features that influence identification and diagnosis. , 1994, AJR. American journal of roentgenology.

[16]  Jun Nakashima,et al.  Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. , 2004, Urology.

[17]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[18]  Masoom A Haider,et al.  Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. , 2007, AJR. American journal of roentgenology.

[19]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[20]  M. Reiser,et al.  Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology. , 2007, AJR. American journal of roentgenology.

[21]  H. Hricak,et al.  Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. , 2010, Urology.

[22]  H. Schlemmer,et al.  Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? , 2004, European Radiology.

[23]  M. Sumura,et al.  Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer , 2008, Acta radiologica.

[24]  Yuri Kitamura,et al.  Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. , 2006, AJR. American journal of roentgenology.

[25]  A. Lopez‐Beltran,et al.  2005 update on pathology of prostate biopsies with cancer. , 2006, European urology.

[26]  P. Stattin,et al.  Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. , 2005, European urology.

[27]  John Kurhanewicz,et al.  Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. , 2008, Magnetic resonance imaging.

[28]  E A Zerhouni,et al.  Nonpalpable prostate cancer: detection with MR imaging. , 1991, Radiology.

[29]  Silvia D. Chang,et al.  Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology , 2006, Journal of magnetic resonance imaging : JMRI.

[30]  K. Taari,et al.  Magnetic resonance imaging of clinically localized prostatic cancer. , 1998, The Journal of urology.

[31]  T. Stamey,et al.  An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. , 2000, The Journal of urology.

[32]  Henkjan J Huisman,et al.  Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. , 2003, Radiology.

[33]  Olivier Rouvière,et al.  Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? , 2007, European Radiology.